SIRT2 and breast cancer: Notably, the TM pseudopeptide decreased tumor size or increased overall survival in two mouse models of breast cancer and induced a G1/G0 cell cycle arrest in MCF7 cells via reduced expression of the oncogene c-Myc, indicating that Sirt2 is an attractive therapeutic target in breast cancer [186].